TP53 mutations as potential prognostic markers for specific cancers: Analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database | bioRxiv
Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes | Oncogene
Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm | ACS Chemical Biology
Implications of driver genes associated with a high tumor mutation burden identified using next‑generation sequencing on immunotherapy in hepatocellular carcinoma
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others | Nature Reviews Clinical Oncology
Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia | Haematologica
Clinical implications of subclonal TP53 mutations in acute myeloid leukemia | Haematologica
TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma
Disarming mutant p53 oncogenic function - ScienceDirect
TP53 alterations of hormone-naïve prostate cancer in the Chinese population | Prostate Cancer and Prostatic Diseases
Five‐year overall survival rate in patients with oncomorphic and... | Download Scientific Diagram
Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines | PNAS
IJMS | Free Full-Text | Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors | HTML
Frontiers | Mutation-Derived Neoantigens for Cancer Immunotherapy
Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells | Breast Cancer Research | Full Text
High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort | Leukemia
Zinc shapes the folding landscape of p53 and establishes a pathway for reactivating structurally diverse cancer mutants | eLife
LRP1B or TP53 mutations are associated with higher tumor mutational burden and worse survival in hepatocellular carcinoma
The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases | Leukemia
The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density | npj Breast Cancer
Mutations of the p53 Gene as a Prognostic Factor in Aggressive B-Cell Lymphoma | NEJM
TP53 mutation spectrum in primary colorectal cancers. a Proportion of... | Download Scientific Diagram
Frontiers | Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies
